重症虚血肢の世界市場レポート 2025年

重症虚血肢市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.3％で55億7,000万米ドルに成長します。予測期間の成長は、再生医療の進歩、早期介入への注力、肥満の有病率の増加、世界ヘルスイニシアチブ、患者教育プログラムに起因しています。予測期間の主な動向には、ウェアラブル医療技術、遠隔医療と遠隔患者モニタリング、人工知能（AI）の統合、患者中心のケアモデル、低侵襲介入などが含まれます。

予想される糖尿病と末梢動脈疾患の急増は、当面の重症虚血肢治療市場の拡大を牽引する構えです。糖尿病は血糖値の上昇を伴う代謝障害を特徴とし、末梢動脈疾患は下肢動脈の狭窄を指し、手足への血流低下につながります。これらの疾患は血管合併症や切断のリスクを著しく高め、重症虚血肢の発生に寄与しています。糖尿病や末梢動脈疾患の有病率の上昇は、重症虚血肢市場の成長の原動力となっています。例えば、2022年1月の国際糖尿病連盟のデータによると、20-79歳の糖尿病の世界有病率は2021年に5億3,660万人に達し、2045年には12.2％増の7億8,320万人になると予想されています。さらに、オックスフォード大学出版局が2023年3月に発行した雑誌によると、2020年には2億人以上が末梢動脈疾患に罹患しており、2045年までに50％近く急増すると予測されています。したがって、これらの疾患の発生率の増加が重症虚血肢治療市場を活性化させています。

重症虚血肢（CLI）治療市場の主要企業は、この深刻なタイプの末梢動脈疾患に罹患した患者の治療成績を改善するために、溶解ステントなどの先進的な製品を革新しています。生体吸収性ステントとして知られる溶解性ステントは、罹患した動脈に一時的なサポートを提供し、血管が治癒するにつれて徐々に溶解するように設計されています。例えば、2024年4月、米国の医療機器会社であるAbbott Laboratories社は、Esprit BTK Everolimus Eluting Resorbable Scaffold Systemの承認をFDAから受けた。このステントは特に膝下動脈の慢性四肢脅威性虚血（CLTI）患者を対象としています。この承認は、米国で初めてこの疾患に対して溶解性ステントが承認されたことを意味します。溶ける縫合糸に似た材料で作られたこのステントは、留置後約3年で溶けるように設計されています。また、免疫抑制剤エベロリムスを放出し、動脈の再狭窄を防ぎ、血管の治癒をサポートします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界重症虚血肢PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の重症虚血肢市場：成長率分析
• 世界の重症虚血肢市場の実績：規模と成長, 2019-2024
• 世界の重症虚血肢市場の予測：規模と成長, 2024-2029, 2034F
• 世界重症虚血肢総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の重症虚血肢市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デバイス
• 薬物
• 手術
• 世界の重症虚血肢市場薬による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 降圧剤
• 抗血小板薬
• 抗血栓剤
• その他の医薬品
• 世界の重症虚血肢市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他の用途
• 世界の重症虚血肢市場、デバイスの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血管形成術用バルーン
• ステント
• カテーテル
• アテローム切除装置
• 埋め込み型デバイス
• 世界の重症虚血肢市場、薬物の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗血小板薬
• 血管拡張薬
• 抗凝固剤
• 血栓溶解剤
• 成長因子とサイトカイン
• 世界の重症虚血肢市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイパス手術
• 動脈内膜切除術
• 切断
• 血行再建術

第7章 地域別・国別分析

• 世界の重症虚血肢市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の重症虚血肢市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 重症虚血肢市場：競合情勢
• 重症虚血肢市場：企業プロファイル
  • Medtronic Plc Overview, Products and Services, Strategy and Financial Analysis
  • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
  • ThermoGenesis Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Pluri Biotech Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Rexgenero Ltd.
• LimFlow SA
• Micro Medical Solutions
• Cardiovascular Systems Inc.
• Cynata Therapeutics Ltd
• Shanghai MicroPort Medical（Group）Co Ltd.
• B. Braun SE
• Teva Pharmaceutical Industries Ltd.
• Aldagen Inc.
• Cook Medical
• Philips
• BD
• Penumbra Inc.
• Cardinal Health Inc.
• Teleflex Incorporated

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 重症虚血肢市場2029：新たな機会を提供する国
• 重症虚血肢市場2029：新たな機会を提供するセグメント
• 重症虚血肢市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Critical limb ischemia treatment involves the restoration of blood flow to areas affected by critical limb ischemia, a chronic condition characterized by severe blockages in the blood vessels of the hands and legs, leading to numbness and pain. Treatment modalities encompass a range of approaches, including medication, surgical interventions using devices, and other therapeutic measures.

The primary types of critical limb ischemia treatment include devices, drugs, and surgery. Embolic protection devices (EPDs) are medical devices designed to trap blood and luminal debris, preventing plaque debris from reaching the distal bed. Medications used in the treatment include antihypertensive agents, antiplatelet drugs, antithrombotic agents, and others. These treatments are administered in various healthcare settings, including hospitals, clinics, and other medical facilities.

The critical limb ischemia market research report is one of a series of new reports from The Business Research Company that provides critical limb ischemia market statistics, including critical limb ischemia industry global market size, regional shares, competitors with a critical limb ischemia market share, detailed critical limb ischemia market segments, market trends and opportunities, and any further data you may need to thrive in the critical limb ischemia industry. This critical limb ischemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The critical limb ischemia market size has grown strongly in recent years. It will grow from $3.6 billion in 2024 to $3.9 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increase in diabetes cases, tobacco consumption, hypertension prevalence, improvements in vascular imaging, growth in endovascular interventions, medical research and clinical trials.

The critical limb ischemia market size is expected to see strong growth in the next few years. It will grow to $5.57 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to regenerative medicine advances, focus on early intervention, increasing prevalence of obesity, global health initiatives, patient education program. Major trends in the forecast period include wearable health technologies, telemedicine and remote patient monitoring, integration of artificial intelligence (AI), patient-centric care models, minimally invasive interventions.

The anticipated surge in diabetes mellitus and peripheral artery diseases is poised to drive the expansion of the critical limb ischemia treatment market in the foreseeable future. Diabetes mellitus characterizes a metabolic disorder involving elevated blood glucose levels, while peripheral artery disease refers to the narrowing of leg arteries, leading to reduced blood flow to the limbs. These conditions significantly heighten the risk of vascular complications and amputation, thereby contributing to the occurrence of critical limb ischemia. The escalating prevalence of diabetes mellitus and peripheral artery diseases acts as a driving force behind the growth of the critical limb ischemia market. For example, as per data from the International Diabetes Federation in January 2022, the global prevalence of diabetes among 20-79-year-olds reached 536.6 million in 2021, expected to rise by 12.2% to 783.2 million by 2045. Furthermore, a journal published by Oxford University Press in March 2023 indicated that over 200 million individuals were affected by peripheral artery diseases in 2020, projected to surge by nearly 50% by 2045. Hence, the increasing incidence of these diseases fuels the critical limb ischemia treatment market.

Leading companies in the critical limb ischemia (CLI) treatment market are innovating advanced products, such as dissolving stents, to improve treatment outcomes for patients affected by this severe type of peripheral artery disease. Dissolving stents, known as bioresorbable stents, are designed to offer temporary support to the affected artery and gradually dissolve as the vessel heals. For instance, in April 2024, Abbott Laboratories, a US-based medical device company, received approval from the Food and Drug Administration (FDA) for the Esprit BTK Everolimus Eluting Resorbable Scaffold System. This stent is specifically aimed at patients with chronic limb-threatening ischemia (CLTI) in arteries below the knee. This approval signifies the first time a dissolving stent has been authorized for this condition in the United States. Made from materials similar to dissolving sutures, the stent is engineered to dissolve over approximately three years after implantation. It also releases the immunosuppressive drug everolimus, which helps prevent the re-narrowing of arteries and supports the healing of the vessel.

Major companies in the critical limb ischemia (CLI) treatment market are developing technologically advanced products, such as dissolving stents, to enhance treatment outcomes for patients with this severe form of peripheral artery disease. Dissolving stents, also referred to as bioresorbable stents, are engineered to provide temporary support to the affected artery and gradually dissolve as the vessel heals. For example, in April 2024, Abbott Laboratories, a US-based medical device manufacturer, received approval from the Food and Drug Administration (FDA) for the Esprit BTK Everolimus Eluting Resorbable Scaffold System. This dissolving stent is intended for patients suffering from chronic limb-threatening ischemia (CLTI) in arteries below the knee. This approval marks the first instance of a dissolving stent being approved for this condition in the United States. The stent is constructed from materials similar to those used in dissolving sutures and is designed to dissolve over approximately three years following implantation. It also releases the immunosuppressive drug everolimus, which aids in preventing the re-narrowing of arteries and promotes vessel healing.

Key players in the critical limb ischemia market are strategically focusing on innovative solutions, such as a clinically engineered immobilization solution for the patient's leg, to establish a competitive edge in the market. These solutions delicately immobilize the patient's leg during fluoroscopy-guided treatments, providing crucial pressure management for individuals prone to painful ulcerations. For instance, in January 2022, Adept Medical, a New Zealand-based medical equipment manufacturer, introduced its Lower Leg Support product. This device is tailored to gently immobilize a patient's leg during fluoroscopy-guided critical limb ischemia treatments. Equipped to perform both endorotation and exorotation, the Lower Leg Support offers versatile positioning options while maintaining the foot in a slightly plantar-flexed posture for optimal imaging. Its ergonomic design aligns the leg to meet procedural requirements for lower limb interventions. The gadget features an adaptable footplate, enabling usage on either the left or right foot. Moreover, if foot manipulation is necessary during the procedure, the footplate can be entirely removed, allowing access for distal artery procedures, ultrasound imaging, and effective pressure management for patients experiencing frequent painful ulcerations. Additionally, the device includes soft foam straps to gently immobilize patients during conscious sedation.

In November 2023, Inari Medical, a US-based medical device company, acquired LimFlow SA for an undisclosed amount. This acquisition is intended to expand Inari Medical's portfolio with innovative technologies that address unmet needs in the treatment of chronic limb-threatening ischemia (CLTI), ultimately enhancing patient outcomes and driving growth. LimFlow SA is a Switzerland-based company specializing in medical devices for the treatment of chronic limb-threatening ischemia (CLTI).

Major companies operating in the critical limb ischemia market include Medtronic Plc, Boston Scientific Corporation, ThermoGenesis Holdings Inc., Abbott Laboratories, Pluri Biotech Ltd., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, Cardiovascular Systems Inc., Cynata Therapeutics Ltd, Shanghai MicroPort Medical (Group) Co Ltd., B. Braun SE, Teva Pharmaceutical Industries Ltd., Aldagen Inc., Cook Medical, Philips, BD, Penumbra Inc., Cardinal Health Inc., Teleflex Incorporated, AngioDynamics Inc., Endologix Inc., Terumo Corporation, Teleflex, MicroPort Scientific, Silk Road Medical, LeMaitre Vascular Inc., Merit Medical Systems Inc., Shockwave Medical, Avinger, Biomerics LLC, Intact Vascular Inc., Soundbite Medical Solutions, Bluegrass Vascular Technologies, PQ Bypass, Vasorum Ltd, Rex Medical, Otsuka Medical Devices, Aortica Corporation

North America was the largest region in the critical limb ischemia treatment market in 2024. The regions covered in the critical limb ischemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the critical limb ischemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The critical limb ischemia treatment market includes revenues earned by entities by providing angioplasty, stents and laser atherectomy treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Critical Limb Ischemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on critical limb ischemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for critical limb ischemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The critical limb ischemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Devices; Drugs; Surgery
• 2) By Medication: Antihypertensive Agents; Antiplatelet Drugs; Antithrombotic Agents; Other Medications
• 3) By Application: Hospital; Clinic; Other Applications
• Subsegments:
• 1) By Devices: Angioplasty Balloons; Stents; Catheters; Atherectomy Devices; Implantable Devices
• 2) By Drugs: Antiplatelet Agents; Vasodilators; Anticoagulants; Thrombolytics; Growth Factors And Cytokines
• 3) By Surgery: Bypass Surgery; Endarterectomy; Amputation; Revascularization Procedures
• Companies Mentioned: Medtronic Plc; Boston Scientific Corporation; ThermoGenesis Holdings Inc.; Abbott Laboratories; Pluri Biotech Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Critical Limb Ischemia Market Characteristics

3. Critical Limb Ischemia Market Trends And Strategies

4. Critical Limb Ischemia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Critical Limb Ischemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Critical Limb Ischemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Critical Limb Ischemia Market Growth Rate Analysis
• 5.4. Global Critical Limb Ischemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Critical Limb Ischemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Critical Limb Ischemia Total Addressable Market (TAM)

6. Critical Limb Ischemia Market Segmentation

• 6.1. Global Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Devices
• Drugs
• Surgery
• 6.2. Global Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihypertensive Agents
• Antiplatelet Drugs
• Antithrombotic Agents
• Other Medications
• 6.3. Global Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• Other Applications
• 6.4. Global Critical Limb Ischemia Market, Sub-Segmentation Of Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angioplasty Balloons
• Stents
• Catheters
• Atherectomy Devices
• Implantable Devices
• 6.5. Global Critical Limb Ischemia Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiplatelet Agents
• Vasodilators
• Anticoagulants
• Thrombolytics
• Growth Factors And Cytokines
• 6.6. Global Critical Limb Ischemia Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bypass Surgery
• Endarterectomy
• Amputation
• Revascularization Procedures

7. Critical Limb Ischemia Market Regional And Country Analysis

• 7.1. Global Critical Limb Ischemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Critical Limb Ischemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Critical Limb Ischemia Market

• 8.1. Asia-Pacific Critical Limb Ischemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Critical Limb Ischemia Market

• 9.1. China Critical Limb Ischemia Market Overview
• 9.2. China Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Critical Limb Ischemia Market

• 10.1. India Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Critical Limb Ischemia Market

• 11.1. Japan Critical Limb Ischemia Market Overview
• 11.2. Japan Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Critical Limb Ischemia Market

• 12.1. Australia Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Critical Limb Ischemia Market

• 13.1. Indonesia Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Critical Limb Ischemia Market

• 14.1. South Korea Critical Limb Ischemia Market Overview
• 14.2. South Korea Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Critical Limb Ischemia Market

• 15.1. Western Europe Critical Limb Ischemia Market Overview
• 15.2. Western Europe Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Critical Limb Ischemia Market

• 16.1. UK Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Critical Limb Ischemia Market

• 17.1. Germany Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Critical Limb Ischemia Market

• 18.1. France Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Critical Limb Ischemia Market

• 19.1. Italy Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Critical Limb Ischemia Market

• 20.1. Spain Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Critical Limb Ischemia Market

• 21.1. Eastern Europe Critical Limb Ischemia Market Overview
• 21.2. Eastern Europe Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Critical Limb Ischemia Market

• 22.1. Russia Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Critical Limb Ischemia Market

• 23.1. North America Critical Limb Ischemia Market Overview
• 23.2. North America Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Critical Limb Ischemia Market

• 24.1. USA Critical Limb Ischemia Market Overview
• 24.2. USA Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Critical Limb Ischemia Market

• 25.1. Canada Critical Limb Ischemia Market Overview
• 25.2. Canada Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Critical Limb Ischemia Market

• 26.1. South America Critical Limb Ischemia Market Overview
• 26.2. South America Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Critical Limb Ischemia Market

• 27.1. Brazil Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Critical Limb Ischemia Market

• 28.1. Middle East Critical Limb Ischemia Market Overview
• 28.2. Middle East Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Critical Limb Ischemia Market

• 29.1. Africa Critical Limb Ischemia Market Overview
• 29.2. Africa Critical Limb Ischemia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Critical Limb Ischemia Market, Segmentation By Medication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Critical Limb Ischemia Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Critical Limb Ischemia Market Competitive Landscape And Company Profiles

• 30.1. Critical Limb Ischemia Market Competitive Landscape
• 30.2. Critical Limb Ischemia Market Company Profiles
  • 30.2.1. Medtronic Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. ThermoGenesis Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pluri Biotech Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Critical Limb Ischemia Market Other Major And Innovative Companies

• 31.1. Rexgenero Ltd.
• 31.2. LimFlow SA
• 31.3. Micro Medical Solutions
• 31.4. Cardiovascular Systems Inc.
• 31.5. Cynata Therapeutics Ltd
• 31.6. Shanghai MicroPort Medical (Group) Co Ltd.
• 31.7. B. Braun SE
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Aldagen Inc.
• 31.10. Cook Medical
• 31.11. Philips
• 31.12. BD
• 31.13. Penumbra Inc.
• 31.14. Cardinal Health Inc.
• 31.15. Teleflex Incorporated

32. Global Critical Limb Ischemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Critical Limb Ischemia Market

34. Recent Developments In The Critical Limb Ischemia Market

35. Critical Limb Ischemia Market High Potential Countries, Segments and Strategies

• 35.1 Critical Limb Ischemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Critical Limb Ischemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Critical Limb Ischemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer